JP2019529418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529418A5 JP2019529418A5 JP2019514748A JP2019514748A JP2019529418A5 JP 2019529418 A5 JP2019529418 A5 JP 2019529418A5 JP 2019514748 A JP2019514748 A JP 2019514748A JP 2019514748 A JP2019514748 A JP 2019514748A JP 2019529418 A5 JP2019529418 A5 JP 2019529418A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutical composition
- composition according
- cancer tumor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148016A JP7470085B2 (ja) | 2016-09-16 | 2021-09-10 | 抗体およびチェックポイント阻害剤の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903724 | 2016-09-16 | ||
| AU2016903724A AU2016903724A0 (en) | 2016-09-16 | Antibody and checkpoint inhibitor combination therapy | |
| PCT/AU2017/050998 WO2018049474A1 (en) | 2016-09-16 | 2017-09-14 | Antibody and checkpoint inhibitor combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148016A Division JP7470085B2 (ja) | 2016-09-16 | 2021-09-10 | 抗体およびチェックポイント阻害剤の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529418A JP2019529418A (ja) | 2019-10-17 |
| JP2019529418A5 true JP2019529418A5 (https=) | 2019-11-28 |
Family
ID=61618508
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514748A Pending JP2019529418A (ja) | 2016-09-16 | 2017-09-14 | 抗体およびチェックポイント阻害剤の併用療法 |
| JP2021148016A Active JP7470085B2 (ja) | 2016-09-16 | 2021-09-10 | 抗体およびチェックポイント阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148016A Active JP7470085B2 (ja) | 2016-09-16 | 2021-09-10 | 抗体およびチェックポイント阻害剤の併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11655304B2 (https=) |
| EP (1) | EP3512548B1 (https=) |
| JP (2) | JP2019529418A (https=) |
| KR (1) | KR20190053909A (https=) |
| CN (1) | CN109789206A (https=) |
| AU (1) | AU2017326751B2 (https=) |
| CA (1) | CA3035262A1 (https=) |
| IL (1) | IL265274B2 (https=) |
| WO (1) | WO2018049474A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2944649C (en) * | 2014-04-04 | 2022-06-21 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
| BR112019005378A2 (pt) * | 2016-09-19 | 2019-08-27 | The Trustees Of The University Of Pennsylvania | molécula de ácido nucleico, composição, e, métodos para prevenir ou tratar uma doença e para induzir uma resposta imune |
| EP3672990A1 (en) | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| JP2021514379A (ja) | 2018-02-21 | 2021-06-10 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｂ７−ｈ４抗体製剤 |
| MA52416A (fr) | 2018-03-02 | 2021-04-21 | Five Prime Therapeutics Inc | Anticorps b7-h4 et leurs procédés d'utilisation |
| EA202191556A1 (ru) * | 2018-12-03 | 2021-10-14 | Фьюжн Фармасьютикалз Инк. | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек |
| CN115151309A (zh) * | 2019-12-05 | 2022-10-04 | Ose免疫疗法 | 抗clec-1a抗体及其抗原结合片段 |
| BR112022018238A2 (pt) | 2020-03-13 | 2022-10-25 | Univ Texas | Método de tratamento de um câncer em um sujeito |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| CN112540178B (zh) * | 2020-08-06 | 2023-12-19 | 武汉天德生物科技有限公司 | 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法 |
| CN112608386B (zh) * | 2020-12-21 | 2022-09-23 | 捷和泰（北京）生物科技有限公司 | 阻断异嗜性人IgM反应性的单克隆抗体及其制备方法 |
| CN112684185B (zh) * | 2020-12-25 | 2024-01-12 | 苏州旭光科星抗体生物科技有限公司 | 一种可溶性b7-h4定量检测试剂盒及其应用 |
| WO2022232255A2 (en) * | 2021-04-28 | 2022-11-03 | The Trustees Of Columbia University In The City Of New York | Antibodies for the treatment and prevention of covid-19 and emerging variants |
| WO2022247756A1 (zh) * | 2021-05-23 | 2022-12-01 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| CN113980125B (zh) * | 2021-10-15 | 2024-03-26 | 中国科学院武汉病毒研究所 | 一种抗sftsv的中和性单克隆抗体及其应用 |
| CN114957457B (zh) * | 2022-05-27 | 2024-09-24 | 中国科学院武汉病毒研究所 | 一种抗ev71病毒中和抗体及其制备方法和应用 |
| CN114989294B (zh) * | 2022-05-27 | 2024-11-05 | 中国科学院武汉病毒研究所 | 一种抗ev71病毒抗体及其制备方法和应用 |
| CN114796483B (zh) * | 2022-06-28 | 2022-11-08 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
| JP2024137479A (ja) * | 2023-03-24 | 2024-10-07 | 富士フイルム株式会社 | 免疫チェックポイント阻害薬による治療効果を予測する方法、上記治療効果を予測するためのデータを得るための方法、上記治療効果を予測する方法又は上記データを得るための方法におけるプロハプトグロビン量の測定のための検査キット |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20050250106A1 (en) | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
| US8278290B2 (en) | 2005-02-14 | 2012-10-02 | Biononics Limited | Tubulin polymerisation inhibitors |
| AU2007211840B2 (en) * | 2006-02-03 | 2012-03-01 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| US8466163B2 (en) | 2006-12-11 | 2013-06-18 | Bionomics Limited | Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization |
| DK2173379T3 (en) * | 2007-07-02 | 2015-12-07 | Oncomed Pharm Inc | Compositions and methods for treatment and diagnosis of cancer |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2013067054A1 (en) * | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| US9341728B2 (en) | 2013-07-29 | 2016-05-17 | Westerngeco L.L.C. | Methods of analyzing seismic data |
| WO2015042108A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
| UA129760C2 (uk) * | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| US10521817B2 (en) | 2014-04-02 | 2019-12-31 | Nant Holdings Ip, Llc | Augmented pre-paid cards, systems and methods |
| CA2944649C (en) * | 2014-04-04 | 2022-06-21 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
| BR112016028838A2 (pt) | 2014-06-11 | 2017-10-24 | Genentech Inc | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017040660A1 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US20200114017A1 (en) * | 2017-06-16 | 2020-04-16 | Bionomics Limited | Antibody drug conjugates that bind lgr5 |
-
2017
- 2017-09-14 KR KR1020197010764A patent/KR20190053909A/ko not_active Ceased
- 2017-09-14 IL IL265274A patent/IL265274B2/en unknown
- 2017-09-14 US US16/333,065 patent/US11655304B2/en active Active
- 2017-09-14 EP EP17849922.4A patent/EP3512548B1/en active Active
- 2017-09-14 CN CN201780056887.8A patent/CN109789206A/zh active Pending
- 2017-09-14 AU AU2017326751A patent/AU2017326751B2/en not_active Ceased
- 2017-09-14 JP JP2019514748A patent/JP2019529418A/ja active Pending
- 2017-09-14 CA CA3035262A patent/CA3035262A1/en active Pending
- 2017-09-14 WO PCT/AU2017/050998 patent/WO2018049474A1/en not_active Ceased
-
2021
- 2021-09-10 JP JP2021148016A patent/JP7470085B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529418A5 (https=) | ||
| JP7470085B2 (ja) | 抗体およびチェックポイント阻害剤の併用療法 | |
| JP2016534157A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2019513809A5 (https=) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2015518008A5 (https=) | ||
| FI4339615T3 (sv) | Anti-PD-1-antikroppar för användande vid behandling av cancer | |
| JP2017511687A5 (https=) | ||
| JP2017533266A5 (https=) | ||
| JP2018070648A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| EP3337514A1 (en) | Compositions, combinations and related methods for photoimmunotherapy | |
| JP2018516966A5 (https=) | ||
| US20170260282A1 (en) | GITR Antibodies, Methods, and Uses | |
| JP6750559B2 (ja) | Ａｌｌｅｒｇｉｎ−１アンタゴニストによるがん免疫増強剤 | |
| JP2020533293A5 (https=) | ||
| JP2020500179A (ja) | 免疫チェックポイント阻害剤と組み合わせた治療的使用のための抗ｂａｇ３抗体 | |
| JPWO2020106736A5 (https=) | ||
| WO2020237304A1 (en) | Antigen-binding molecules that bind the active conformation of platelet integrin receptor gpiib/iiia | |
| JPWO2020150439A5 (https=) | ||
| ES2946343T3 (es) | Anticuerpos anti-CD137 para combinación con anticuerpos anti-PD-L1 | |
| NZ750974B2 (en) | Antibody and checkpoint inhibitor combination therapy | |
| RU2022102309A (ru) | Биомаркеры для определения эффективности ингибиторов иммунных контрольных точек | |
| RU2020109716A (ru) | Противоопухолевое средство и усилитель противоопухолевого действия |